Table 1 A meta-analysis comparing LMWH in the treatment of venous thromboembolism
From: Low-molecular-weight heparins in the treatment of venous thromboembolism
Adverse event | LMWH | Unfractionated heparin | RR (95% CI) | P |
|---|---|---|---|---|
Recurrent venous thromboembolism | 96/2212 (4.3%) | 115/2235 (5.1%) | 0.85 (0.65-1.12) | 0.20 |
Major haemorrhage | 33/2212 (1.5%) | 57/2235 (2.5%) | 0.63 (0.37-1.05) | 0.08 |
Total mortality | 98/2006 (4.9%) | 132/2027 (6.5%) | 0.76 (0.59-0.98) | 0.03 |